HuiYong Zhao

HuiYong Zhao

Auto-generated profile, based on publicly available information

HuiYong Zhao

Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
RYRona Yaeger
Rona Yaeger
RMRiccardo Mezzadra
Riccardo Mezzadra
JSJenna Sinopoli
Jenna Sinopoli
YBYu Bian
Yu Bian
MMMichelangelo Marasco
Michelangelo Marasco
SMSandra Misale
Sandra Misale
With the combination of KRASG12C and EGFR inhibitors, KRAS is becoming a druggable target in colorectal cancer. However, secondary resistance limits its efficacy. Using cell lines, patient-derived xenografts, and patient samples, we detected a heterogeneous pattern of putative resistance alterations expected primarily to prevent inhibition of ERK signaling by drugs at progression. Serial analysis of patient blood samples on treatment demonstrates that most of these alterations are detected at a low frequency except for KRASG12C amplification, a recurrent resistance mechanism that rises in step with clinical progression. Upon drug withdrawal, resistant cells with KRASG12C amplification undergo oncogene-induced senescence, and progressing patients experience a rapid fall in levels of this alteration in circulating DNA. In this new state, drug resumption is ineffective as mTOR signaling is elevated. However, our work exposes a potential therapeutic vulnerability, whereby therapies that target the senescence response may overcome acquired resistance. Significance: Clinical resistance to KRASG12C–EGFR inhibition primarily prevents suppression of ERK signaling. Most resistance mechanisms are subclonal, whereas KRASG12C amplification rises over time to drive a higher portion of resistance. This recurrent resistance mechanism leads to oncogene-induced senescence upon drug withdrawal and creates a potential vulnerability to senolytic approaches. Watch the interview with Sandra Misale, PhD, recipient of the 2025 Cancer Discovery Early Career Award: https://vimeo.com/1100471486 This article is highlighted in the In This Issue feature, p. 1

26 February 2026 in Science
Verified
Journal Article
Closed access
SHSophie A. Hanina
Sophie A. Hanina
TPTyler Park
Tyler Park
MLMichael Lopez
Michael Lopez
VRVinagolu K. Rajasekhar
Vinagolu K. Rajasekhar
JMJorge Mansilla-Soto
Jorge Mansilla-Soto
MSMichel Sadelain
Michel Sadelain
Solid tumor antigen heterogeneity is a major challenge for cancer immunotherapies, including chimeric antigen receptor (CAR) T cells. Unlike CD19 for B cell malignancies, no target with pan-cellular expression in solid tumors and absence in normal vital cells has been identified. CD70 is a promising candidate, physiologically confined to immune cell subsets and aberrantly expressed in many cancers. We show that heterogeneous CD70 expression in tumors is epigenetically regulated, ranging from high to very low in individual cells, appearing negative by conventional detection methods. Using a highly sensitive CD70 receptor, HLA-independent T cell (HIT) receptor coexpressing CD80 and 4-1BBL for costimulation, we efficiently eliminated CD70-heterogeneous tumors that evade prototypic CAR T cells. These findings provide a potential strategy to treat a broad range of solid tumors.

4 June 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
YCYanyan Cai
Yanyan Cai
PZPeihua Zhao
Peihua Zhao
FWFan Wu
Fan Wu
HZHuiyong Zhao
Huiyong Zhao
HSHong Shao
Hong Shao
SCSarat Chandarlapaty
Sarat Chandarlapaty
Endocrine resistance is frequently encountered in estrogen receptor–positive (ER+) breast cancer, often because of somatic mutations such as neurofibromin 1 ( NF1 ) loss. The mechanisms by which ER-directed proliferation is lost in such cases are unknown, limiting the potential use of additional endocrine treatments. Here, we performed CRISPR-Cas9 knockout (KO) screens and found that nuclear receptor subfamily 2 group F member 2 (NR2F2), an orphan nuclear receptor, was essential for NF1 loss–induced endocrine resistance. Induction of NR2F2 was observed in ER+ cell line models and patient samples and occurred via activation of the mitogen-activated protein kinase (MAPK) pathway upon NF1 loss or other MAPK pathway genetic alterations. Mechanistically, increased NR2F2 orchestrated a repressed ER transcriptional program by repartitioning the ER cistrome, altering the balance of its associated transcriptional coregulators, and modifying global chromatin accessibility. Accordingly, genetic depletion or pharmacologic inhibition of NR2F2 restored sensitivity to hormone therapies in multiple models, including ER+ cell lines, patient-derived xenografts, and patient-derived organoid-based xenografts harboring diverse endocrine-resistance mechanisms such as NF1 , AT-rich interactive domain-containing protein 1A ( ARID1A ), phoshatase and tensin homolog ( PTEN ) loss, or Kirsten rat sarcoma virus ( KRAS ) overexpression. Together, these findings underscore NR2F2 as a critical modulator of the hormone response pathway and suggest its inhibition as a promising strategy to overcome endocrine resistance in breast cancer.

3 April 2023
Verified
Other
Open access
VAVito Amodio
Vito Amodio
RYRona Yaeger
Rona Yaeger
PAPamela Arcella
Pamela Arcella
CCCarlotta Cancelliere
Carlotta Cancelliere
SLSimona Lamba
Simona Lamba
SMSandra Misale
Sandra Misale

3 April 2023
Verified
Other
Open access
VAVito Amodio
Vito Amodio
RYRona Yaeger
Rona Yaeger
PAPamela Arcella
Pamela Arcella
CCCarlotta Cancelliere
Carlotta Cancelliere
SLSimona Lamba
Simona Lamba
SMSandra Misale
Sandra Misale

27 July 2023
Verified
Other
Open access
RYRona Yaeger
Rona Yaeger
RMRiccardo Mezzadra
Riccardo Mezzadra
JSJenna Sinopoli
Jenna Sinopoli
YBYu Bian
Yu Bian
MMMichelangelo Marasco
Michelangelo Marasco
SMSandra Misale
Sandra Misale
Patients Longitudinal Cell Free DNA data